Blog & Guides

In-depth articles on DEA reporting, diversion prevention programs, regulatory compliance, and investigative practice — written by a practitioner for practitioners.

Program Design
How to Report Drug Diversion: A Step-by-Step Guide for Healthcare Staff

Who to tell, what to document, and when a report must reach the DEA — a practical reporting guide for pharmacy staff, nurses, and compliance officers.

2026-09-21 Read →
Insights
Waste Documentation and Independent Witness Requirements

Wasting controlled substances alone, or with a witness who doesn't actually watch the syringe emptied and disposed of, defeats the control…

2026-09-20 Read →
Regulatory
How Long Does a DEA Investigation Take? Timeline & What Happens

A realistic walkthrough of the DEA investigation timeline — from complaint or audit finding to referral, and what registrants should do during the process.

2026-09-19 Read →
Insights
Patient Complaints: An Underused Diversion Signal

A pattern of complaints that a specific medication 'isn't working' or arrives short could signal tampering or substitution rather than a su…

2026-09-19 Read →
Program Design
Signs of Medication Diversion: 15 Red Flags for Pharmacy & Nursing Leaders

The behavioral, documentation, and inventory red flags that point to medication diversion — with a practical monitoring checklist.

2026-09-17 Read →
Insights
DEA Renewal Lapses: A Hidden Diversion Blind Spot

A lapsed DEA registration for any prescriber or the pharmacy itself can silently disable controlled substance ordering checks—verify renewa…

2026-09-16 Read →
Program Design
What Is Drug Diversion in Healthcare? Definition, Examples & Warning Signs

The definition of drug diversion in hospitals and pharmacies, how it happens, who's typically involved, and the warning signs every program should monitor.

2026-09-15 Read →
Insights
Compounding Room Accountability: Witness Every Waste Event

Require two staff to witness and sign every controlled-substance waste event in the compounding room—single-signature logs are the easiest…

2026-09-15 Read →
Insights
Auditing Pharmacy Tech Access to Controlled Substances

Review pharmacy tech system permissions regularly — access should match current job duties, and any override or unlock privilege beyond tha…

2026-09-14 Read →
Compounding
USP 795 Nonsterile Compounding: Diversion Risks in the Compounding Area

How USP 795 nonsterile compounding workflows create diversion risk — and the controls that keep compounded preparations accountable.

2026-09-13 Read →
Regulatory
Controlled Substance Recordkeeping: Every Document a DEA Audit Checks

The complete recordkeeping framework for controlled substances — inventory records, receiving/dispensing logs, transfer records, and the two-year retention rule.

2026-09-11 Read →
Insights
Closing the Loop on Return-to-Stock Discrepancies

When a returned dose is credited back to inventory without a second verifier confirming vial, quantity, and condition match the original di…

2026-09-11 Read →
Insights
Audit Witness Pairing Patterns to Close Waste Documentation Gaps

Collusion risk rises when the same two employees consistently pair for waste witnessing. Audit co-signer combinations routinely — identical…

2026-09-10 Read →
DEA Reporting
CSOS: Electronic Ordering of Schedule II Controlled Substances Explained

How the Controlled Substance Ordering System (CSOS) replaces paper DEA Form 222 — certificates, digital signatures, supplier setup, and what to keep for the records.

2026-09-09 Read →
Insights
Patient Complaints: A Frequently Overlooked Drug Diversion Signal

Patient complaints about medications not working, missing doses, or receiving altered capsules can signal active diversion — route these…

2026-09-09 Read →
Regulatory
Reverse Distribution of Controlled Substances: Returns Without the Diversion Risk

How to return expired or unusable controlled substances through DEA-registered reverse distributors — and where diversion risk hides in the returns process.

2026-09-08 Read →
DEA Reporting
DEA Form 41: How to Properly Destroy or Dispose of Controlled Substances

When and how to use DEA Form 41 for disposal of unwanted, expired, or unusable controlled substances — including the destruction witness requirements and recordkeeping.

2026-09-07 Read →
Program Design
Drug Diversion in Ambulatory Surgery Centers: Closing the Gap With No Pharmacist On Site

ASCs handle controlled substances with no on-site pharmacist, small teams, and often no separation of duties. How to close the waste-documentation and access gap in outpatient surgery settings.

2026-09-06 Read →
Regulatory
Surviving a DEA Inspection: Audit Prep for Diversion Prevention Programs

What DEA investigators look for during a controlled substances inspection, and how to keep your diversion prevention program audit-ready.

2026-09-05 Read →
Program Design
AI Drug Diversion Surveillance Isn't Self-Enforcing: Build the Alert-to-Action Workflow

STAT reported that hospital managers ignored machine-learning diversion alerts before a travel nurse diverted opioids. Why surveillance tools only work with triage, ownership, SLAs, and documented follow-through.

2026-09-04 Read →
Regulatory
Telehealth Prescribing of Controlled Substances in 2026: Expiring Flexibilities and the Online Pharmacy Crackdown

The COVID telemedicine flexibilities expire Dec 31, 2026, DEA's special registration rule is still pending, and Operation Meltdown shut down 200+ illegal online pharmacies. What diversion teams must verify at the counter.

2026-09-03 Read →
Regulatory
Corresponding Responsibility: The Pharmacist's Legal Duty to Spot Diversion

The legal duty that makes every pharmacist the last checkpoint against prescription drug diversion — and how to document it.

2026-09-01 Read →
Insights
Blind Witnessing: A Hidden Gap in Waste Documentation

Blind witnessing — when a colleague signs off on waste without observing the disposal — is a common diversion gap. Confirm your policy…

2026-08-31 Read →
Real-World Cases
Sole-Pharmacist Shifts and Diversion Risk: Lessons from the Lancaster, NH Case

A per-diem pharmacist pleaded guilty to diverting stimulants and benzodiazepines while working solo shifts at a New Hampshire pharmacy. What the case teaches about coverage, cameras, and shift-change counts.

2026-08-31 Read →
Supply Chain
DSCSA and Diversion Prevention: How Track-and-Trace Strengthens Your Program

The Drug Supply Chain Security Act's unit-level tracing, suspect product rules, and what they mean for controlled substance diversion programs.

2026-08-30 Read →
Insights
Patient Complaints: An Overlooked Signal in Diversion Detection Programs

When patients report that their pain medication isn't working or that pills look different, these complaints may signal diversion.

2026-08-30 Read →
Compounding
USP 800 Hazardous Drugs: Safe Handling Meets Diversion Prevention

The overlap between hazardous drug handling standards and controlled substance diversion prevention in oncology and beyond.

2026-08-28 Read →
Insights
Why Controlled Substance Count Reconciliation Stops Diversion Early

Unexplained count discrepancies — even small ones — can signal diversion. Review controlled substance count records daily and investigate…

2026-08-28 Read →
Insights
Lapsed DEA Registrations: A Pharmacy Diversion Red Flag

Confirm prescriber DEA registrations are current before dispensing controlled substances. A lapsed registration may signal a provider who…

2026-08-27 Read →
Compounding
USP 797 and Sterile Compounding: Where Diversion Hides in the IV Room

How diversion happens in sterile compounding — high-value injectables, partial doses, and waste documentation gaps — and the controls that close it.

2026-08-26 Read →
Insights
Audit Pharmacy Tech Access Controls to Catch Diversion Early

Pharmacy techs should each have unique credentials scoped to their role — shared logins eliminate individual accountability and make it…

2026-08-25 Read →
Regulatory
DEA Form 222: Ordering Schedule II Controlled Substances — A Complete Guide

How DEA Form 222 works: obtaining forms, completing them correctly, CSOS electronic ordering, supplier requirements, and recordkeeping.

2026-08-24 Read →
High-Risk Settings
Anesthesia & OR Drug Diversion: Prevention Strategies for High-Risk Settings

Why the operating room is a high-risk diversion environment, and the controls that reduce risk for anesthesia providers and perioperative teams.

2026-08-22 Read →
Analytics
Drug Diversion Surveillance Without Expensive Software: A SQL + Analytics Playbook

How to build practical diversion surveillance with the data you already have — SQL patterns for waste, overrides, and provider behavior.

2026-08-20 Read →
Program Design
10 Components of a Drug Diversion Prevention Program

The ten elements every credible drug diversion prevention program needs — from governance to surveillance to continuous improvement.

2026-08-18 Read →
Regulatory
DEA Warns of Electronic Prescription Fraud: Fake E-Scripts for Controlled Substances

The DEA has identified large-scale e-script fraud — tens of thousands of fake controlled-substance prescriptions filled using stolen clinician credentials. What pharmacists must verify and how to report it.

2026-08-17 Read →
DEA Reporting
DEA Form 106 vs. Preliminary Notification: The 1-Business-Day Rule Explained

The two-step reporting framework for theft or significant loss of controlled substances — and why the one-business-day rule matters.

2026-08-16 Read →
Certification
PTCB CSDP Certificate: Study Guide & Exam Prep for Pharmacy Technicians

Everything technicians need to know about the PTCB Controlled Substances Diversion Prevention Certificate — eligibility, exam format, and what to study.

2026-08-14 Read →
Policy & Practice
Controlled Substance Waste & Discrepancy Documentation: Policies That Pass Audits

How to document medication waste, partial doses, and discrepancies so your diversion prevention program survives an audit.

2026-08-12 Read →
DEA Reporting
How to File DEA Form 106: A Step-by-Step Guide for Pharmacies

When to file, the one-business-day preliminary notification rule, the 45-day deadline, and how to complete the form without common mistakes.

2026-08-10 Read →
Regulatory
Controlled Substance Inventory Requirements: DEA Rules for Pharmacies Explained

DEA biennial inventory requirements, what must be counted, when to count, and how to keep the records audit-ready.

2026-08-10 Read →